JPET Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McNay, J. L.
Right arrow Articles by Goldberg, L. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McNay, J. L.
Right arrow Articles by Goldberg, L. I.
Journal of Pharmacology And Experimental Therapeutics, Vol. 151, Issue 1, 23-31, 1966
Copyright © 1966 by American Society for Pharmacology and Experimental Therapeutics

COMPARISON OF THE EFFECTS OF DOPAMINE, ISOPROTERENOL, NOREPINEPHRINE AND BRADYKININ ON CANINE RENAL AND FEMORAL BLOOD FLOW

John L. McNay 1 and Leon I. Goldberg 1

1 Department of Medicine (Section of Clinical Pharmacology) and Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia

The effects of arterial injections of dopamine on femoral and renal blood flow were compared with those of isoproterenol, norepinephrine and bradykinin after POB pretreatment. Dopamine was found to have a vasodilator action on the hind limb, which was antagonized by pronethalol and DCI. The potency of dopamine as a femoral vasodilating agent was very low compared to that of isoproterenol. In contrast, dopamine caused renal vasodilation by a qualitatively different mechanism, as indicated by a higher relative potency within the series of adrenergic agonists and the lack of antagonism by selective beta adrenergic blockade. This property cannot be attributed to conversion of dopamine to tetrahydropapaveroline which causes renal vasodilation by a beta adrenergic mechanism. Also, the metabolism of dopamine to norepinephrine,3,4-dihydroxyphenylacetic acid or 3-methoxy-4-hydroxyphenylethylamine is not the basis for this property. Furthermore, the renal vasodilation was not antagonized by atropine or eliminated by reserpine pretreatment. The ability of dopamine to dilate the renal vascular bed without producing a qualitatively similar direct effect on the femoral vascular bed sets it apart from agents such as papaverine and the nitrites. The physiologic significance of the renal vascular effects of dopamine remains to be determined.

Accepted on August 24, 1965




This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
N. Weitl and R. Seifert
Distinct Interactions of Human {beta}1- and {beta}2-Adrenoceptors with Isoproterenol, Epinephrine, Norepinephrine, and Dopamine
J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 760 - 769.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
F. A. TIBAYAN, A. N. CHESNUTT, H. G. FOLKESSON, J. EANDI, and M. A. MATTHAY
Dobutamine Increases Alveolar Liquid Clearance in Ventilated Rats by Beta-2 Receptor Stimulation
Am. J. Respir. Crit. Care Med., July 1, 1997; 156(2): 438 - 444.
[Abstract] [Full Text]

Home page
 ScienceHome page
D Cantacuzene, K. Kirk, D. McCulloh, and C. Creveling
Effect of fluorine substitution on the agonist specificity of norepinephrine
Science, June 15, 1979; 204(4398): 1217 - 1219.
[Abstract] [PDF]

Home page
 Cardiovasc ResHome page
A. Delin, P. Olsson, and A.-C. Teger-Nilsson
Vasodilatation in the Canine Leg caused by Intra-arterial Infusion of Thrombin and Tissue Thromboplastin
Cardiovasc Res, October 1, 1967; 1(4): 371 - 378.
[Abstract] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1966 by the American Society for Pharmacology and Experimental Therapeutics.